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Alzheimer’s disease (AD) is characterized by the accumulation of Aβ peptides, hyper-
phosphorylated tau proteins, and neuronal loss in the brain of affected patients. The
causes of neurodegeneration in AD are not clear, but apoptosis could be one of the cell
death mechanisms. According to the amyloid hypothesis, abnormal aggregation of Aβ
leads to altered kinase activities inducing tau phosphorylation and neuronal degeneration.
Several studies have shown that pro-apoptotic kinases could be a link between Aβ and
tau anomalies. Here, we present recent evidences from AD experimental models and
human studies that three pro-apoptotic kinases (double-stranded RNA kinase (PKR),
glycogen synthase kinase-3β, and C-Jun terminal kinase (JNK) could be implicated in AD
physiopathology. These kinases are detectable in human fluids and the analysis of their
levels could be used as potential surrogate markers to evaluate cell death and clinical
prognosis. In addition to current biomarkers (Aβ1–42, tau, and phosphorylated tau), these
new evaluations could bring about valuable information on potential innovative therapeutic
targets to alter the clinical evolution.
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Introduction
Neuropathological lesions in Alzheimer’s disease (AD) include senile plaques, neurofibrillary tan-
gles, and amyloid angiopathy leading to synaptic and neuronal degradations. Aβ is formed after the
cleavage of amyloid precursor protein (APP) by β secretase (BACE1) and γ secretase (1). According
to the amyloid cascade hypothesis (2), biochemical and genetic findings have suggested that Aβ
accumulation can induce tau phosphorylation and aggregation, synaptic dysfunction, and neuronal
alteration, responsible for clinical signs of dementia (3). The precisemechanisms of neuronal demise
have not been fully elucidated; however, apoptosis has been one of the most analyzed mechanisms
in previous reports. Apoptosis is a sequence of events leading to the activation of caspases and
cell disintegration. It has been proposed as the predominant form of cell death in AD due to
unbalanced actions between pro and anti-apoptotic proteins (4, 5). Increased expression of several
pro-apoptotic kinases has been observed in AD brains and their cellular pathways could be linked
to AD physiopathology (6–13).
Protein kinases represent one of the largest super families, and they are molecular switches
activating and inhibiting many biological processes, such as memory, differentiation, cell division,
and cell death. They belong to complex metabolisms interacting with other kinases and their
dysfunctions can be associated with various diseases (14). According to Hardy’s hypothesis (3), Aβ
peptides can trigger protein kinases in AD participating in neuronal signaling pathways between Aβ
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and tau phosphorylation. Many of these kinases are also pro-
apoptotic and could induce synaptic and neuronal sheddings.
Recently, reports have shown that cerebrospinal fluid (CSF)
levels of Aβ1–42, total tau (T-tau), and phosphorylated tau (ptau)
were altered in AD patients and in patients with mild cog-
nitive impairment (MCI) with higher risks to convert to AD
(15). The analysis of CSF biomarkers has brought about new
insights into the managing procedures of AD patients leading to
new diagnostic criteria (16). The levels of these CSF biomark-
ers correlate with the severity of neuropathological lesions (17,
18). The use of CSF biomarkers has improved the confidence
of clinicians for AD diagnosis (19) and now serves for the
screening of patients in clinical trials (20). Because lumbar
puncture (LP) is better known, more practiced, and well tol-
erated (21–24), physicians resort in CSF biomarkers more and
more in clinical practice reflecting the impact on AD diagnosis
(25, 26).
However, these classic CSF biomarkers are not directly predic-
tive of the AD evolution. The need for new biomarkers remains
to avoid the classification of patients by quintiles or clusters (27,
28). Furthermore, they have several pre-analytical requirements
limiting the analysis to expert centers while AD patients are
located everywhere in the world (29–31). Consequently, addi-
tional biomarkers are needed to predict the clinical evolution
and cognitive decline, and to assess the efficiency of treatment
targeting pathways of neuronal death.
This brief report will provide an overview of three pro-
apoptotic protein kinases that are involved inADphysiopathology
with detectable levels in biological fluids. We aim to address their
place as new biomarkers reflecting the rate of neuronal death,
predicting possibly the clinical evolution and requiring less pre-
analytical preparations.
Pro-Apoptotic Kinases in Alzheimer’s
Disease
Double-Stranded RNA-Dependent Protein Kinase
Involvement of PKR in AD Pathophysiology
RNA-dependent protein kinase (PKR) is a serine/threonine pro-
apoptotic kinase present in cells as non-activated. PKR plays a role
in various cell functions (32) and is involved in apoptosis (33–40).
Activation of PKR results from autophosphorylation on threo-
nine residues 446 and 451 of the kinase domain (41–45). Once
activated, PKR triggers several effectors and pathways leading to
apoptosis including the activation of eukaryotic initiating factor
2 alpha (eiF2α), which inhibits protein synthesis. PKR partici-
pates in the activation of caspase 8, which can contribute to the
conversion of procaspase 3 into caspase 3 (46, 47). More widely,
PKR activates both intrinsic and extrinsic apoptotic pathways (38,
48–51). Activated and pro-apoptotic forms of PKR (pPKR) can
accumulate in several neurodegenerative diseases including AD
(9, 12, 52–54). In 2002, we have observed an abnormal activation
of PKR in AD brains (9) and this result was confirmed by several
teams (12, 52, 53). Immunohistochemical findings performed
in AD brains revealed an accumulation of pPKR around senile
plaques (in dystrophic neurites), in the cytoplasm of neurons
especially in the hippocampus and the temporal cortex, whereas
neuronal staining was more nuclear in the frontal and parietal
cortex (8, 55, 56).
Using animal and cells models, we have shown that PKR is
activated by Aβ peptide (8, 53, 55–61) through its activator PACT
(56), and this activation plays a role in neuronal death in AD (8,
55, 56), Furthermore, we have shown that the activation of PKR
(partly by Aβ) could control the levels of β-secretase (BACE1) in
stressed cells. These data suggest the existence of a pathological
self-sustaining loop involvingPKR (1).On the other hand,wehave
reported a co-localization of ptau and pPKR (8). In neural cell cul-
tures, Aβ induced the phosphorylation of PKR, glycogen synthase
kinase-3β (GSK-3β), and tau. The pharmacological inhibition of
PKR reduced GSK-3 activation and tau phosphorylation, suggest-
ing that PKR could indirectly control the abnormal formation of
tangles (8). Moreover, PKR has been shown to be implicated in
memory (62). All these findings suggest that PKR plays a key role
in the events leading to abnormal molecular signals at the origin
of neurodegeneration in AD.
PKR as a New Biomarker
The analysis of PKR levels in biological fluids of AD patients was
further explored. In 2006, we observed increased pPKR levels in
lymphocytes from AD patients compared to controls. However,
an important overlap between the two groups was found showing
that this biological test was not appropriate for diagnosis (63). The
CSF is in direct contact with the brain and is less influenced by
peripheral factors. We have evaluated CSF PKR concentrations
in AD, MCI, and control individuals. Ninety one patients were
included. The levels of total PKR (T-PKR), pPKR, Aβ, T-tau, and
ptau were determined by Western blots or ELISA methods. The
concentrations of T-PKR and pPKR were significantly increased
in AD patients and in most MCI patients compared to neuro-
logical controls. The optimal threshold for pPKR to discriminate
AD patients from controls gave a sensitivity of 91.1% and a
specificity of 94.3%. In the group of AD patients, concentrations
of pPKR correlated with CSF levels of tau and ptau. A few AD
or MCI patients with normal Aβ and tau levels had increased
pPKR levels. A correct discrimination between non-AD subjects
and AD patients was possible with CSF PKR evaluations (11).
To understand if pPKR and ptau could be found in extracellular
fluid after the induction of neural endoplasmic reticulum (ER)
stress, we have carried out a study in the supernatant of stressed
human neuroblastoma cells. Results have revealed an increased
concentration of T-PKR, pPKR, T-tau, and ptau after cellular
stress. pPKR, together with tau, are released from neural cells
due to an increased membrane permeability of unknown origin
or late breakdown of the apoptotic plasma membrane. The fact
that especially pPKR is increased in AD CSF (317%) and much
less T-PKR (38%) could suggest that mainly pPKR accumulates in
affected neurons before being released in the extracellular space of
AD brains (11).
In a second step, we have analyzed in the same cohort, the
predictive value of CSF pPKR levels on the cognitive decline over
2 years (11, 64). Every 6months, patients underwent neurologi-
cal exams and neuropsychological assessments including a Mini
Mental State Examination (MMSE) evaluation. Using a multivari-
ate linear mixed model, our results showed that the level of CSF
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pPKR was associated with a more pronounced cognitive decline.
In this cohort, CSF pPKR levels were the only biomarkers linked
to the cognitive decline over the follow-up survey. Furthermore,
although classical biomarkers are very useful to predict the clinical
outcome ofMCI patients, the results of biomarker levels in the two
groups of amnestic MCI patients (converters and non-converters)
show that PKR was the most discriminant biomarker between the
two groups (64).
Glycogen Synthase Kinase-3 Protein Kinase
GSK-3β and AD Pathophysiology
Glycogen synthase kinase-3 (GSK-3) is a proline-directed ser-
ine/threonine kinase and is ubiquitously expressed with two iso-
forms, GSK-3α and GSK-3β (65, 66). GSK-3 has a role in many
biological pathways including gene transcription, apoptosis (67),
regulation of glycogen metabolism (68, 69), and microtubule sta-
bility (70, 71). GSK-3β is highly present in neurons (72) and can
phosphorylate tau at 17 sites of the protein, more extensively than
any other kinases (71). It is activated on two phosphorylation sites
(Tyrosine 216 and Serine 9), which have opposite effects. Tyr216
phosphorylation leads to GSK-3β activation while serine 9 phos-
phorylation inhibits its activity (66). Evidences from several works
have suggested that the involvement of GSK-3 in AD is linked
to the reduction of acetylcholine synthesis (66) and to increased
production of Aβ. GSK-3β can co-localize with ptau in dystrophic
neurites and tangles (8, 73, 74). Enhanced GSK-3 protein levels
and activity were observed in the frontal cortex and hippocampus
inADbrains (8). Furthermore, in 2012, we have shown that pPKR,
activated GSK-3β, and ptau proteins can be co-expressed in AD
brains. In addition, PKR canmodulate neuronal apoptosis and tau
phosphorylation through GSK-3β activation. GSK-3 inhibition
decreased tau phosphorylation without acting on PKR activation
(8). It has recently been reported that a polymorphism in the
GSK-3 promoter region is a risk factor for late onset AD (75). We
have also shown that active Aβ immunotherapy in AD patients
induced a reduction of all GSK-3β forms; active, inactive, and
total (76). Overall, the inactive GSK-3β appears to be the more
abundant form compared to the active form. Finally, GSK-3 is pro-
apoptotic and therebymight directly contribute to neuronal death
in AD (67).
GSK-3 as a Biomarker
In 2004, Hye et al. explored GSK-3 levels in circulating lympho-
cytes. Total GSK-3α and β and inactive GSK-3β concentrations
were assessed inwhite blood cells in a series of 113 patients includ-
ing AD, MCI, and elderly controls. The results showed increased
GSK-3α (+65%) and GSK-3β (+59%) protein levels in AD and
MCI compared to controls without concomitant augmentation of
pGSK-3β (77).
In 2004, a decreased level of CSF GSK-3β in schizophrenic
patients from a small cohort has been shown (78). The study did
not evaluate activated or inactivated form of the kinase and so far
no study has assessed CSF GSK-3 concentrations in AD patients.
Taking together, measurements of GSK-3 in biological fluids
could be a supplemental biomarker reflecting AD pathology.
Since GSK-3 is dramatically decreased in AD brains after active
Aβ immunization (76), CSF GSK-3 evaluation could reflect the
efficiency of this therapeutic on neuronal stress and pro-apoptotic
pathways.
C-Jun N-Terminal Kinases
JNK and AD Pathophysiology
C-Jun N-terminal kinases (JNKs) are a family of serine/threonine
protein kinases encoded by three genes (JNK1, JNK2, and JNK3).
JNK1 and JNK2 are ubiquitous, and JNK3 is mainly expressed
in the brain. JNKs are activated by phosphorylation (pJNK)
through mitogen-activated protein (MAP) kinase kinase path-
ways induced by extracellular stimuli, such as cytokines and Aβ
peptides (79). JNKs have multiple functions, including regulation
of gene expression, inflammation, cell proliferation, and apoptosis
(80). In the brain, while JNK1 and 2 are involved in the devel-
opment, JNK3 seems principally implicated in neurodegeneration
(81). Previous studies have revealed that JNKs, particularly JNK3,
can control BACE1 expression levels (82), can phosphorylate APP,
and enhance Aβ production (83, 84). The deletion of JNK3 has
a neuroprotective effect against ischemia (85) and excitotoxicity
(86, 87). Aβ-induced cell death is reduced in cultures of cortical
neurons from JNK3 knockout (KO) mice, and JNKs have been
implicated in experimental models of AD and Parkinson’s dis-
ease. pJNK is increased in AD brains as well as upstream JNKs
activators (88).
Immunohistochemical findings in AD brains have shown that
the activated form of JNK (pJNK) was localized in peripheral rims
of senile plaques, in neurofibrillary tangles, and granulovacuolar
degenerations, as previously reported (7, 88). Neurons were mod-
estly marked in the cytoplasm and in the nucleus in AD brains. In
control brains, pJNK immunolabellings were rarely detected. The
full form of JNK3 was detected, in the center and around senile
plaques, as well as in the cytoplasm of neurons. Confocal imaging
revealed an association between Aβ42 and JNK3 stainings in
senile plaques, suggesting that JNK3 proteins may accumulate
during the formation of amyloid aggregates (7). Immunochemical
results revealed a significant correlation between Aβ and JNK3
levels in control and AD brains. In frontal cortex, pJNK and JNK3
could be detected in the same senile plaques. Quantification of
these histological results showed an increase of JNK3 staining
(+59%) and pJNK staining (+182%) in AD brains compared to
control brains (7).
JNK as a CSF Biomarker
According to these results, JNK3 could be a marker of abnormal
pathways in the CSF. In a recent study, CSF JNKs levels were
evaluated by western blots in AD patients and neurological con-
trols. JNK1, JNK2, and pJNK proteins were not detectable in the
CSF. A significant increase of CSF JNK3 levels was found in AD
patients compared to controls (+23%). Optimal cut-offs showed
that the JNK3 value of 70.3 optical density units (ODU) had a
sensitivity of 80% and a specificity of 73%, with an area under
curve of 0.75 (7). No correlations were found between CSF JNK3
levels and age, sex, CSF levels of Aβ1–42, T-tau, and pTau, as
well as MRI evaluations using Fazekas scores (89) or Scheltens
scales (90).
Patients with ADwere followed for a mean period of 1.8 (1.3)
years. During the follow-up, clinicians performed 4.7 (2.25)
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MMSE tests per patient. Using linearmixedmodels, a longitudinal
analysis using tertiles of JNK3 levels was carried out. We found
that patients in the third tertile (>89ODU) experienced a reduced
and significant decline in MMSE scores over time. This associa-
tionwasmaintained after adjusting for age, sex, educational levels,
and MRI abnormalities. Comparison of the tertiles revealed that
patients in the two lowest tertiles (<89 ODU) experienced a more
rapid decline of MMSE scores over time than those in the upper
tertile (7).
Conclusion
Apoptosis seems an important way of cellular death inAD. Several
pro-apoptotic kinases are involved in the pathophysiology of AD,
and the evaluations of CSF concentrations could be useful to pre-
dict the cognitive decline. In addition, since these three kinases are
implicated in neuronal apoptosis, they represent new therapeutic
targets that could afford neuroprotection and alter the relentless
clinical evolution in AD patients.
References
1. Yan R, Vassar R. Targeting the beta secretase BACE1 for Alzheimer’s
disease therapy. Lancet Neurol (2014) 13:319–29. doi:10.1016/S1474-4422(13)
70276-X
2. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis.
Science (1992) 256:184–5. doi:10.1126/science.1566067
3. Hardy J. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal.
J Neurochem (2009) 110:1129–34. doi:10.1111/j.1471-4159.2009.06181.x
4. Lucassen PJ, Chung WC, Kamphorst W, Swaab DF. DNA damage distribution
in the human brain as shown by in situ end labeling; area-specific differences in
aging and Alzheimer disease in the absence of apoptotic morphology. J Neu-
ropathol Exp Neurol (1997) 56:887–900. doi:10.1097/00005072-199708000-
00007
5. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl
J Med (2003) 348:1365–75. doi:10.1056/NEJMra022366
6. Checler F, Alves da Costa C. p53 in neurodegenerative diseases and brain
cancers. Pharmacol Ther (2014) 142:99–113. doi:10.1016/j.pharmthera.2013.
11.009
7. Gourmaud S, Paquet C, Dumurgier J, Pace C, Bouras C, Gray F, et al. Increased
levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to
cognitive decline. J Psychiatry Neurosci (2015) 40(3):151–61. doi:10.1503/jpn.
140062
8. Bose A, Mouton-Liger F, Paquet C, Mazot P, Vigny M, Gray F, et al. Modulation
of tau phosphorylation by the kinase PKR: implications in Alzheimer’s disease.
Brain Pathol (2011) 21:189–200. doi:10.1111/j.1750-3639.2010.00437.x
9. Chang RC, Wong AK, Ng HK, Hugon J. Phosphorylation of eukaryotic ini-
tiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in
Alzheimer’s disease. Neuroreport (2002) 13:2429–32. doi:10.1097/00001756-
200212200-00011
10. Garcia MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C, et al. Impact of
protein kinase PKR in cell biology: from antiviral to antiproliferative action.
Microbiol Mol Biol Rev (2006) 70:1032–60. doi:10.1128/MMBR.00027-06
11. Mouton-Liger F, Paquet C, Dumurgier J, Lapalus P, Gray F, Laplanche JL, et al.
Increased cerebrospinal fluid levels of double-strandedRNA-dependant protein
kinase in Alzheimer’s disease. Biol Psychiatry (2012) 71:829–35. doi:10.1016/j.
biopsych.2011.11.031
12. Peel AL, Bredesen DE. Activation of the cell stress kinase PKR in Alzheimer’s
disease and human amyloid precursor protein transgenic mice. Neurobiol Dis
(2003) 14:52–62. doi:10.1016/S0969-9961(03)00086-X
13. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two
phase 3 trials of bapineuzumab inmild-to-moderateAlzheimer’s disease.NEngl
J Med (2014) 370:322–33. doi:10.1056/NEJMoa1304839
14. Shchemelinin I, Sefc L, Necas E. Protein kinases, their function and implication
in cancer and other diseases. Folia Biol (2006) 52(3):81–100.
15. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and
plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6:131–44.
doi:10.1038/nrneurol.2010.4
16. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas
CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommenda-
tions from the national institute on aging-Alzheimer’s association workgroups
on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement (2011)
7:263–9. doi:10.1016/j.jalz.2011.03.005
17. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H,
et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of
Alzheimer-type pathologic changes in the brain. Arch Neurol (2009) 66:382–9.
doi:10.1001/archneurol.2008.596
18. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM,
et al. Relationships between biomarkers in aging and dementia. Neurology
(2009) 73:1193–9. doi:10.1212/WNL.0b013e3181bc010c
19. Mouton-Liger F, Wallon D, Troussiere AC, Yatimi R, Dumurgier J, Magnin E,
et al. Impact of cerebro-spinal fluid biomarkers of Alzheimer’s disease in clinical
practice: a multicentric study. J Neurol (2014) 261:144–51. doi:10.1007/s00415-
013-7160-3
20. Dumurgier J, Laplanche JL, Mouton-Liger F, Lapalus P, Indart S, Prevot M,
et al. The screening of Alzheimer’s patients with CSF biomarkers, modulates
the distribution of APOE genotype: impact on clinical trials. J Neurol (2014)
261:1187–95. doi:10.1007/s00415-014-7335-6
21. Paquet C, Latour F, Saulnier I, Hanon O. [Multicenter study on lumbar punc-
ture indication, clinical practice and feasibility]. Rev Neurol (Paris) (2012)
168:28–32. doi:10.1016/j.neurol.2011.08.012
22. Heitz C, Lorette A, Julian A, Roubaud C, Paquet C. [Lumbar puncture practice
in case of hemorrhagic or ischemic risk: a national opinion survey]. Rev Neurol
(2014) 170:685–92. doi:10.1016/j.neurol.2014.05.007
23. Peskind E, Nordberg A, Darreh-Shori T, Soininen H. Safety of lumbar puncture
procedures in patients with Alzheimer’s disease. Curr Alzheimer Res (2009)
6:290–2. doi:10.2174/156720509788486509
24. Zetterberg H, Tullhog K, Hansson O, Minthon L, Londos E, Blennow K.
Low incidence of post-lumbar puncture headache in 1,089 consecutivememory
clinic patients. Eur Neurol (2010) 63:326–30. doi:10.1159/000311703
25. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de
Ven PM, et al. Cerebrospinal fluid markers for differential dementia diagnosis
in a large memory clinic cohort.Neurology (2012) 78:47–54. doi:10.1212/WNL.
0b013e31823ed0f0
26. Troussiere AC, Wallon D, Mouton-Liger F, Yatimi R, Robert P, Hugon J, et al.
Who needs cerebrospinal biomarkers? A national survey in clinical practice. J
Alzheimers Dis (2014) 40:857–61. doi:10.3233/JAD-132672
27. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF
biomarkers predict a more malignant outcome in Alzheimer disease.Neurology
(2010) 74:1531–7. doi:10.1212/WNL.0b013e3181dd4dd8
28. Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk
EJ, Scheltens P, et al. CSF biomarkers predict rate of cognitive decline in
Alzheimer disease. Neurology (2009) 73:1353–8. doi:10.1212/WNL.
0b013e3181bd8271
29. Dumurgier J, VercruysseO, Paquet C, Bombois S, Chaulet C, Laplanche JL, et al.
Intersite variability of CSF Alzheimer’s disease biomarkers in clinical setting.
Alzheimers Dement (2013) 9:406–13. doi:10.1016/j.jalz.2012.06.006
30. Gabelle A, Dumurgier J, Vercruysse O, Paquet C, Bombois S, Laplanche JL, et al.
Impact of the 2008-2012 French Alzheimer plan on the use of cerebrospinal
fluid biomarkers in research memory center: the PLM study. J Alzheimers Dis
(2013) 34:297–305. doi:10.3233/JAD-121549
31. Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Delaby C, et al.
Impact of harmonization of collection tubes on Alzheimer’s disease diagno-
sis. Alzheimers Dement (2014) 10(5 Suppl):S390–4.e2. doi:10.1016/j.jalz.2013.
06.008
32. Proud CG. PKR: a new name and new roles. Trends Biochem Sci (1995)
20:241–6. doi:10.1016/S0968-0004(00)89025-8
33. Lee SB, Esteban M. The interferon-induced double-stranded RNA-activated
protein kinase induces apoptosis. Virology (1994) 199:491–6. doi:10.1006/viro.
1994.1151
Frontiers in Neurology | www.frontiersin.org August 2015 | Volume 6 | Article 1684
Paquet et al. Pro-apoptotic kinases in cerebrospinal fluid
34. Castelli JC, Hassel BA, Maran A, Paranjape J, Hewitt JA, Li XL, et al. The role
of 2’-5’ oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ
(1998) 5:313–20. doi:10.1038/sj.cdd.4400352
35. Cotman CW, Su JH. Mechanisms of neuronal death in Alzheimer’s disease.
Brain Pathol (1996) 6:493–506. doi:10.1111/j.1750-3639.1996.tb00878.x
36. Der SD, Yang YL, Weissmann C, Williams BR, double-stranded A. RNA-
activated protein kinase-dependent pathway mediating stress-induced apopto-
sis. Proc Natl Acad Sci U S A (1997) 94:3279–83. doi:10.1073/pnas.94.7.3279
37. Kibler KV, Shors T, Perkins KB, Zeman CC, Banaszak MP, Biesterfeldt J, et al.
Double-stranded RNA is a trigger for apoptosis in vaccinia virus-infected cells.
J Virol (1997) 71:1992–2003.
38. Srivastava SP, Kumar KU, Kaufman RJ. Phosphorylation of eukaryotic trans-
lation initiation factor 2 mediates apoptosis in response to activation of
the double-stranded RNA-dependent protein kinase. J Biol Chem (1998)
273:2416–23. doi:10.1074/jbc.273.4.2416
39. Takizawa T, Ohashi K, Nakanishi Y. Possible involvement of double-stranded
RNA-activated protein kinase in cell death by influenza virus infection. J Virol
(1996) 70:8128–32.
40. YeungMC,ChangDL,CamantigueRE, LauAS. Inhibitory role of the host apop-
togenic gene PKR in the establishment of persistent infection by encephalomy-
ocarditis virus in U937 cells. Proc Natl Acad Sci U S A (1999) 96:11860–5.
doi:10.1073/pnas.96.21.11860
41. Carpick BW, Graziano V, Schneider D, Maitra RK, Lee X, Williams BR. Char-
acterization of the solution complex between the interferon-induced, double-
stranded RNA-activated protein kinase andHIV-I trans-activating region RNA.
J Biol Chem (1997) 272:9510–6. doi:10.1074/jbc.272.14.9510
42. Dey M, Cao C, Dar AC, Tamura T, Ozato K, Sicheri F, et al. Mechanistic
link between PKR dimerization, autophosphorylation, and eIF2alpha substrate
recognition. Cell (2005) 122:901–13. doi:10.1016/j.cell.2005.06.041
43. Galabru J, Hovanessian A. Autophosphorylation of the protein kinase depen-
dent on double-stranded RNA. J Biol Chem (1987) 262:15538–44.
44. Hovanessian AG. The double stranded RNA-activated protein kinase induced
by interferon: dsRNA-PK. J Interferon Res (1989) 9:641–7. doi:10.1089/jir.1989.
9.641
45. Zhang F, Romano PR, Nagamura-Inoue T, Tian B, Dever TE,MathewsMB, et al.
Binding of double-stranded RNA to protein kinase PKR is required for dimer-
ization and promotes critical autophosphorylation events in the activation loop.
J Biol Chem (2001) 276:24946–58. doi:10.1074/jbc.M102108200
46. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K, Barber GN. Activa-
tion of the dsRNA-dependent protein kinase, PKR, induces apoptosis through
FADD-mediated death signaling. EMBO J (1998) 17:6888–902. doi:10.1093/
emboj/17.23.6888
47. Gil J, Esteban M. The interferon-induced protein kinase (PKR), triggers apop-
tosis through FADD-mediated activation of caspase 8 in a manner independent
of Fas and TNF-alpha receptors. Oncogene (2000) 19:3665–74. doi:10.1038/sj.
onc.1203710
48. Clemens MJ, Hershey JW, Hovanessian AC, Jacobs BC, Katze MG, Kauf-
man RJ, et al. PKR: proposed nomenclature for the RNA-dependent protein
kinase induced by interferon. J Interferon Res (1993) 13:241. doi:10.1089/jir.
1993.13.241
49. DonzeO,Deng J, Curran J, Sladek R, PicardD, SonenbergN. The protein kinase
PKR: a molecular clock that sequentially activates survival and death programs.
EMBO J (2004) 23:564–71. doi:10.1038/sj.emboj.7600078
50. Gil J, Alcami J, Esteban M. Induction of apoptosis by double-stranded-
RNA-dependent protein kinase (PKR) involves the alpha subunit of eukary-
otic translation initiation factor 2 and NF-kappaB. Mol Cell Biol (1999) 19:
4653–63.
51. Scheuner D, Patel R, Wang F, Lee K, Kumar K, Wu J, et al. Double-
stranded RNA-dependent protein kinase phosphorylation of the alpha-subunit
of eukaryotic translation initiation factor 2 mediates apoptosis. J Biol Chem
(2006) 281:21458–68. doi:10.1074/jbc.M603784200
52. Bando Y, Onuki R, Katayama T, Manabe T, Kudo T, Taira K, et al. Double-
strand RNA dependent protein kinase (PKR) is involved in the extrastriatal
degeneration in Parkinson’s disease and Huntington’s disease. Neurochem Int
(2005) 46:11–8. doi:10.1016/j.neuint.2004.07.005
53. Onuki R, Bando Y, Suyama E, Katayama T, Kawasaki H, Baba T, et al. An
RNA-dependent protein kinase is involved in tunicamycin-induced apoptosis
and Alzheimer’s disease. EMBO J (2004) 23:959–68. doi:10.1038/sj.emboj.
7600049
54. Hu JH, Zhang H, Wagey R, Krieger C, Pelech SL. Protein kinase and protein
phosphatase expression in amyotrophic lateral sclerosis spinal cord. J Neu-
rochem (2003) 85:432–42. doi:10.1046/j.1471-4159.2003.01670.x
55. Mouton-Liger F, Paquet C, Dumurgier J, Bouras C, Pradier L, Gray F, et al.
Oxidative stress increases BACE1 protein levels through activation of the PKR-
eIF2alpha pathway. Biochim Biophys Acta (2012) 1822:885–96. doi:10.1016/j.
bbadis.2012.01.009
56. Paquet C, Mouton-Liger F, Meurs EF, Mazot P, Bouras C, Pradier L, et al. The
PKR activator PACT is induced by Abeta: involvement in Alzheimer’s disease.
Brain Pathol (2012) 22:219–29. doi:10.1111/j.1750-3639.2011.00520.x
57. Ito M, Onuki R, Bando Y, Tohyama M, Sugiyama Y. Phosphorylated PKR
contributes the induction of GRP94 under ER stress. Biochem Biophys Res
Commun (2007) 360:615–20. doi:10.1016/j.bbrc.2007.06.087
58. Mecha M, Torrao AS, Mestre L, Carrillo-Salinas FJ, Mechoulam R, Guaza
C. Cannabidiol protects oligodendrocyte progenitor cells from inflammation-
induced apoptosis by attenuating endoplasmic reticulum stress. Cell Death Dis
(2012) 3:e331. doi:10.1038/cddis.2012.71
59. Shimazawa M, Ito Y, Inokuchi Y, Hara H. Involvement of double-stranded
RNA-dependent protein kinase in ER stress-induced retinal neuron damage.
Invest Ophthalmol Vis Sci (2007) 48:3729–36. doi:10.1167/iovs.06-1122
60. Singh M, Fowlkes V, Handy I, Patel CV, Patel RC. Essential role of PACT-
mediated PKR activation in tunicamycin-induced apoptosis. J Mol Biol (2009)
385:457–68. doi:10.1016/j.jmb.2008.10.068
61. Vaughn LS, Snee B, Patel RC. Inhibition of PKR protects against tunicamycin-
induced apoptosis in neuroblastoma cells. Gene (2014) 536:90–6. doi:10.1016/
j.gene.2013.11.074
62. Zhu PJ, HuangW, Kalikulov D, Yoo JW, Placzek AN, Stoica L, et al. Suppression
of PKR promotes network excitability and enhanced cognition by interferon-
gamma-mediated disinhibition. Cell (2011) 147:1384–96. doi:10.1016/j.cell.
2011.11.029
63. Paccalin M, Pain-Barc S, Pluchon C, Paul C, Besson MN, Carret-Rebillat AS,
et al. Activated mTOR and PKR kinases in lymphocytes correlate with memory
and cognitive decline in Alzheimer’s disease. Dement Geriatr Cogn Disord
(2006) 22:320–6. doi:10.1159/000095562
64. Dumurgier J, Mouton-Liger F, Lapalus P, PrevotM, Laplanche JL, Hugon J, et al.
Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer’s disease.
PLoS One (2013) 8:e53587. doi:10.1371/journal.pone.0053587
65. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-
3/factor A. EMBO J (1990) 9:2431–8.
66. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer’s disease.
J Neurochem (2008) 104:1433–9. doi:10.1111/j.1471-4159.2007.05194.x
67. Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in
the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol (2006)
79:173–89. doi:10.1016/j.pneurobio.2006.07.006
68. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal
muscle. Separation from cyclic-AMP-dependent protein kinase and phospho-
rylase kinase. Eur J Biochem (1980) 107:519–27. doi:10.1111/j.1432-1033.1980.
tb06059.x
69. Woodgett JR, Cohen P. Multisite phosphorylation of glycogen synthase. Molec-
ular basis for the substrate specificity of glycogen synthase kinase-3 and
casein kinase-II (glycogen synthase kinase-5). Biochim Biophys Acta (1984)
788:339–47. doi:10.1016/0167-4838(84)90047-5
70. Anderton BH, Betts J, Blackstock WP, Brion JP, Chapman S, Connell J, et al.
Sites of phosphorylation in tau and factors affecting their regulation. Biochem
Soc Symp (2001) 67:73–80.
71. Brion JP, Anderton BH, Authelet M, Dayanandan R, Leroy K, Lovestone S,
et al. Neurofibrillary tangles and tau phosphorylation.Biochem Soc Symp (2001)
67:81–8.
72. Leroy K, Boutajangout A, Authelet M, Woodgett JR, Anderton BH, Brion JP.
The active form of glycogen synthase kinase-3beta is associated with gran-
ulovacuolar degeneration in neurons in Alzheimer’s disease. Acta Neuropathol
(2002) 103:91–9. doi:10.1007/s004010100435
73. Pei JJ, Braak E, BraakH, Grundke-Iqbal I, Iqbal K,Winblad B, et al. Distribution
of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for
Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol (1999)
58:1010–9. doi:10.1097/00005072-199909000-00011
74. ElyamanW, Yardin C, Hugon J. Involvement of glycogen synthase kinase-3beta
and tau phosphorylation in neuronal Golgi disassembly. J Neurochem (2002)
81:870–80. doi:10.1046/j.1471-4159.2002.00838.x
Frontiers in Neurology | www.frontiersin.org August 2015 | Volume 6 | Article 1685
Paquet et al. Pro-apoptotic kinases in cerebrospinal fluid
75. Mateo I, Vazquez-Higuera JL, Sanchez-Juan P, Rodriguez-Rodriguez E, Infante
J, Garcia-Gorostiaga I, et al. Epistasis between tau phosphorylation regulating
genes (CDK5R1 and GSK-3beta) and Alzheimer’s disease risk. Acta Neurol
Scand (2009) 120:130–3. doi:10.1111/j.1600-0404.2008.01128.x
76. Amin J, Paquet C, Baker A, Asuni AA, Love S, Holmes C, et al. Effect of Abeta
immunisation on hyperphosphorylated tau: a potential role for GSK-3beta.
Neuropathol Appl Neurobiol (2015) 41(4):445–57. doi:10.1111/nan.12205
77. Hye A, Kerr F, Archer N, Foy C, Poppe M, Brown R, et al. Glycogen synthase
kinase-3 is increased in white cells early in Alzheimer’s disease. Neurosci Lett
(2005) 373:1–4. doi:10.1016/j.neulet.2004.10.031
78. Kozlovsky N, Regenold WT, Levine J, Rapoport A, Belmaker RH, Agam G.
GSK-3beta in cerebrospinal fluid of schizophrenia patients. J Neural Transm
(2004) 111:1093–8. doi:10.1007/s00702-003-0127-0
79. Daher A, Laraki G, SinghM,Melendez-Pena CE, Bannwarth S, Peters AH, et al.
TRBP control of PACT-induced phosphorylation of protein kinase R is reversed
by stress.Mol Cell Biol (2009) 29:254–65. doi:10.1128/MCB.01030-08
80. Wei W, Norton DD, Wang X, Kusiak JW. Abeta 17-42 in Alzheimer’s dis-
ease activates JNK and caspase-8 leading to neuronal apoptosis. Brain (2002)
125:2036–43. doi:10.1093/brain/awf205
81. Bogoyevitch MA. The isoform-specific functions of the c-Jun N-terminal
Kinases (JNKs): differences revealed by gene targeting. Bioessays (2006)
28:923–34. doi:10.1002/bies.20458
82. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, et al.
Oxidative stress activates a positive feedback between the gamma- and beta-
secretase cleavages of the beta-amyloid precursor protein. J Neurochem (2008)
104(3):683–95. doi:10.1111/j.1471-4159.2007.05072.x
83. Colombo A, Bastone A, Ploia C, Sclip A, Salmona M, Forloni G, et al. JNK
regulates APP cleavage and degradation in a model of Alzheimer’s disease.
Neurobiol Dis (2009) 33:518–25. doi:10.1016/j.nbd.2008.12.014
84. Yoon SO, Park DJ, Ryu JC, Ozer HG, Tep C, Shin YJ, et al. JNK3 perpetuates
metabolic stress induced by Abeta peptides. Neuron (2012) 75:824–37. doi:10.
1016/j.neuron.2012.06.024
85. Kuan CY, Whitmarsh AJ, Yang DD, Liao G, Schloemer AJ, Dong C, et al. A
critical role of neural-specific JNK3 for ischemic apoptosis. Proc Natl Acad Sci
U S A (2003) 100:15184–9. doi:10.1073/pnas.2336254100
86. Brecht S, Kirchhof R, Chromik A, Willesen M, Nicolaus T, Raivich G, et al.
Specific pathophysiological functions of JNK isoforms in the brain. Eur J
Neurosci (2005) 21:363–77. doi:10.1111/j.1460-9568.2005.03857.x
87. Yang DD, Kuan CY, Whitmarsh AJ, Rincon M, Zheng TS, Davis RJ, et al.
Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lack-
ing the Jnk3 gene. Nature (1997) 389:865–70. doi:10.1038/38154
88. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, et al. Activation
and redistribution of c-jun N-terminal kinase/stress activated protein kinase in
degenerating neurons in Alzheimer’s disease. J Neurochem (2001) 76:435–41.
doi:10.1046/j.1471-4159.2001.00046.x
89. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal
abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J
Roentgenol (1987) 149:351–6. doi:10.2214/ajr.149.2.351
90. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al.
Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease
and normal ageing: diagnostic value and neuropsychological correlates. J Neurol
Neurosurg Psychiatry (1992) 55:967–72. doi:10.1136/jnnp.55.10.967
Conflict of Interest Statement: Claire Paquet, Julien Dumurgier, and Jacques
Hugon are investigators in Aβ immunotherapy trials for Lilly and Eisai. Jacques
Hugon is a consultant for Roche in relation toAβ immunotherapy trials. In our part,
studies on PKR were funded by French Alzheimer Plan, studies on GSK-3β were
funded by NEURAD (Marie Curie funding), studies on JNK received University
and INSERM funding. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript. Patent and license:
CSF PKR levels received a world patented and license «Méthodes de diagnostic des
maladies neurodégénératives »(BE11754519.4 PCT/IB2011/053571).
Copyright © 2015 Paquet, Dumurgier and Hugon. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Neurology | www.frontiersin.org August 2015 | Volume 6 | Article 1686
